All In Biotech

Drug Trial Radar · NCT07594106

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Phase 1/2 Study of REGN15505 (a PSMAx4-1BB Bispecific Antibody) Administered Alone or in Combination With Cemiplimab or REGN4336 (a PSMAxCD3 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

265

Planned (sponsor's estimate)

Start

Jul 20, 2026

Primary completion

Oct 27, 2030

Study completion Oct 27, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use of REGN15505 when administered alone, in combination with cemiplimab, or in combination with REGN4336 for: * Any side effects of study drugs * How well the study drugs work * How much REGN15505, cemiplimab, and REGN4336 are in the blood at different times * If the body makes antibodies to REGN15505 or REGN4336, which may mean the study drugs will not work as well as expected * What is the best dose of REGN15505 when administered alone and with cemiplimab and the best dose of REGN15505 and REGN4336 when used in combination

Conditions

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

  • REGN15505Drug

    Administered per protocol

  • REGN15505+CemiplimabDrug

    Administered per protocol

  • REGN15505+REGN4336Drug

    Administered per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to 5 years
  2. Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 5 years
  3. Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 5 years
  4. Occurrence of Adverse Events of Special Interest (AESIs)Time frame: Up to 5 years
  5. Composite Response (CompR) based on ≥50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic assessment of complete response (CR) or partial response (PR)Time frame: Up to 5 years
  6. Objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Up to 5 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Phoenix

    Goodyear, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • H. Lee Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • City of Hope Chicago, City of Hope Cancer Center Chicago

    Zion, Illinois · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.